. 2019 Mar 11;133(22):2436–2444. doi: 10.1182/blood-2018-09-876318

Table 3.

Comparison of brain volumes experiencing metabolic stress between cohorts

	No disease-modifying therapy, median (IQR)	Hydroxyurea therapy, median (IQR)	Chronic transfusion therapy, median (IQR)	P
White matter volume (%)
OEF threshold >40%	48.1 (21.9-64.3)^*^,^†	32.3 (6.3-47.3)^*^,^¶	6.1 (2.5-25.5)^†^,^¶	<.001^‡
OEF threshold >42.5%	36.0 (13.1-59.3)^*^,^†	20.4 (3.6-36.7)^*^,^¶	3.9 (1.3-15.3)^†^,^¶	.001^‡
OEF threshold >45%	22.1 (8.6-49.4)^†	11.2 (2.2-25.4)^¶	2.1 (0.7-10.9)^†^,^¶	.002^‡

Significant difference between cohort not receiving disease-modifying therapy vs cohort receiving HU.

^†

Significant difference between cohort not receiving disease-modifying therapy vs cohort receiving CTT.

^‡

Statistically significant.

^¶

Significant difference between cohort receiving HU vs cohort receiving CTT.